{"classes":[{"categories":[{"measurements":[{"comment":"the upper limit was not reached","groupId":"OG000","lowerLimit":"1.6","upperLimit":"NA","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) is defined as the time from study start until disease progression or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.\n\nMLN9708","id":"OG000","title":"MLN9708"}],"paramType":"MEDIAN","populationDescription":"5 of the 12 patients withdrew prior to progression and therefore progression free survival was censored at their time of withdraw.","reportingStatus":"POSTED","timeFrame":"24 months after initiation of study treatment","title":"Median Progression Free Survival Time","type":"SECONDARY","unitOfMeasure":"months"}